These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 11406520)

  • 1. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.
    Barrera P; Joosten LA; den Broeder AA; van de Putte LB; van Riel PL; van den Berg WB
    Ann Rheum Dis; 2001 Jul; 60(7):660-9. PubMed ID: 11406520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis.
    Joosten LA; Radstake TR; Lubberts E; van den Bersselaar LA; van Riel PL; van Lent PL; Barrera P; van den Berg WB
    Arthritis Rheum; 2003 Feb; 48(2):339-47. PubMed ID: 12571842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment.
    Ulfgren AK; Gröndal L; Lindblad S; Khademi M; Johnell O; Klareskog L; Andersson U
    Ann Rheum Dis; 2000 Jun; 59(6):439-47. PubMed ID: 10834861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis.
    Smeets TJ; Barg EC; Kraan MC; Smith MD; Breedveld FC; Tak PP
    Ann Rheum Dis; 2003 Jul; 62(7):635-8. PubMed ID: 12810425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
    Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N
    Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis.
    van Roon JA; Hartgring SA; Wenting-van Wijk M; Jacobs KM; Tak PP; Bijlsma JW; Lafeber FP
    Ann Rheum Dis; 2007 May; 66(5):664-9. PubMed ID: 17185327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy.
    Baeten D; Demetter P; Cuvelier CA; Kruithof E; Van Damme N; De Vos M; Veys EM; De Keyser F
    J Pathol; 2002 Mar; 196(3):343-50. PubMed ID: 11857499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium.
    Wijbrandts CA; Dijkgraaf MG; Kraan MC; Vinkenoog M; Smeets TJ; Dinant H; Vos K; Lems WF; Wolbink GJ; Sijpkens D; Dijkmans BA; Tak PP
    Ann Rheum Dis; 2008 Aug; 67(8):1139-44. PubMed ID: 18055470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.
    Paleolog EM; Young S; Stark AC; McCloskey RV; Feldmann M; Maini RN
    Arthritis Rheum; 1998 Jul; 41(7):1258-65. PubMed ID: 9663484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis.
    Ulfgren AK; Andersson U; Engström M; Klareskog L; Maini RN; Taylor PC
    Arthritis Rheum; 2000 Nov; 43(11):2391-6. PubMed ID: 11083259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the cytokine network among tumor necrosis factor alpha, interleukin-1beta, interleukin-8, and interleukin-1 receptor antagonist in monosodium urate crystal-induced rabbit arthritis.
    Matsukawa A; Yoshimura T; Maeda T; Takahashi T; Ohkawara S; Yoshinaga M
    Lab Invest; 1998 May; 78(5):559-69. PubMed ID: 9605181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor.
    Ernestam S; af Klint E; Catrina AI; Sundberg E; Engström M; Klareskog L; Ulfgren AK
    Arthritis Res Ther; 2006; 8(1):R18. PubMed ID: 16507118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.
    Woolley DE; Tetlow LC
    Arthritis Res; 2000; 2(1):65-74. PubMed ID: 11219391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients.
    Schuerwegh AJ; Van Offel JF; Stevens WJ; Bridts CH; De Clerck LS
    Rheumatology (Oxford); 2003 Apr; 42(4):541-8. PubMed ID: 12649401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory effects of systemic anti-tumour necrosis factor alpha treatment in human/murine SCID arthritis.
    Schädlich H; Ermann J; Biskop M; Falk W; Sperling F; Jüngel A; Lehmann J; Emmrich F; Sack U
    Ann Rheum Dis; 1999 Jul; 58(7):428-34. PubMed ID: 10381487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
    Dai SM; Nishioka K; Yudoh K
    Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation.
    den Broeder AA; Joosten LA; Saxne T; Heinegård D; Fenner H; Miltenburg AM; Frasa WL; van Tits LJ; Buurman WA; van Riel PL; van de Putte LB; Barrera P
    Ann Rheum Dis; 2002 Apr; 61(4):311-8. PubMed ID: 11874832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of TNFalpha and IL1beta in rheumatoid arthritis synovial fibroblasts by leukotriene B4.
    Xu S; Lu H; Lin J; Chen Z; Jiang D
    Rheumatol Int; 2010 Jul; 30(9):1183-9. PubMed ID: 19809821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
    Popa C; Netea MG; Radstake T; Van der Meer JW; Stalenhoef AF; van Riel PL; Barerra P
    Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA).
    Roelofs MF; Wenink MH; Brentano F; Abdollahi-Roodsaz S; Oppers-Walgreen B; Barrera P; van Riel PL; Joosten LA; Kyburz D; van den Berg WB; Radstake TR
    Ann Rheum Dis; 2009 Sep; 68(9):1486-93. PubMed ID: 18765427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.